Business Context and Reporting Period
Company: CorMedix Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: CorMedix is a development-stage biopharmaceutical company focused on treating cardiorenal disease. The company has no approved products and has generated no product revenue since its inception in 2006. Its primary activities involve the development of two lead product candidates: CRMD003 (Neutrolin), a catheter lock solution to prevent infections in hemodialysis patients, and CRMD001 (deferiprone), intended to prevent contrast-induced nephropathy (CIN). In March 2010, the company completed an Initial Public Offering (IPO).
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,905,236) | $(8,121,455) |
| Accumulated Deficit | $(36,236,279) | $(25,331,043) |
| Cash and Cash Equivalents | $8,283,684 | $1,505,179 |
| Total Assets | $8,847,800 | $2,225,652 |
| Total Liabilities | $1,592,402 | $16,934,551 |
| Net Cash Used in Operating Activities | $(3,668,404) | $(2,146,454) |
| Net Cash Provided by Financing Activities | $10,457,270 | $2,271,621 |
Debt Status: As of December 31, 2010, the company had no outstanding debt. All senior convertible notes and related party notes were converted into common stock or units in connection with the March 2010 IPO.
Material Changes Versus Prior Period
- Capital Structure: The most significant change was the completion of the IPO in March 2010, which generated net proceeds of approximately $10.5 million. This resulted in a substantial increase in cash balances from $1.5 million in 2009 to $8.3 million in 2010.
- Debt Elimination: Total liabilities decreased from approximately $16.9 million in 2009 to $1.6 million in 2010. This reduction was driven by the conversion of approximately $18.9 million in principal and accrued interest from convertible notes into equity.
- Operating Expenses: Total operating expenses increased to $8.5 million in 2010 from $6.1 million in 2009.
- R&D Expenses: Increased to $5.5 million (from $4.9 million), driven by clinical trial costs for CRMD001, manufacturing costs for CRMD003, and stock-based compensation related to the IPO.
- G&A Expenses: Increased to $3.0 million (from $1.2 million), primarily due to costs associated with becoming a public company (legal, accounting, investor relations) and stock-based compensation for executive officers.
- Other Income: The company recorded $391,168 in other income in 2010, primarily from federal grants under the Qualifying Therapeutic Discovery Project program, compared to zero in 2009.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes that existing cash resources ($8.3 million) are sufficient to fund projected operating requirements into the first quarter of 2012. The company expects to continue incurring significant operating losses as it advances clinical trials for CRMD003 and CRMD001. Additional financing will be required to complete development and commercialization.
Development Milestones:
- CRMD003: Submitted an Investigational Device Exemption (IDE) to the FDA in Q4 2010. Commenced CE Mark application process in Europe. A pivotal clinical trial is expected to begin in 2011.
- CRMD001: Enrolled the 30th patient in a Phase II biomarker "proof of concept" study for CIN in February 2011. Interim analysis is expected by the end of Q1 2011.
Risks and Contingencies:
- Going Concern: The company has a history of losses and no revenue. Continued operations depend on raising additional capital, which may be dilutive.
- Regulatory Approval: There is no assurance that product candidates will receive FDA or international regulatory approval. Failure to obtain approval would prevent commercialization.
- Intellectual Property: The company relies on licensed technology from Shiva Biomedical and ND Partners. Termination of these agreements could materially harm the business.
- Stock Volatility: The stock price has been volatile, and the company has a limited operating history.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $8.3 million cash balance to fund operations through Q1 2012, considering the high burn rate of clinical development.
- License Agreements: Review the terms of the Shiva Contribution Agreement and NDP License Agreement, specifically the milestone payment obligations (up to $10 million for Shiva and $3 million for NDP) and termination clauses.
- Clinical Trial Progress: Monitor the enrollment and interim analysis results of the CRMD001 Phase II study and the FDA's decision on the CRMD003 IDE.
- Dilution Risk: Note the existence of approximately 4.3 million warrants outstanding (exercise price $3.4375) and 1.7 million stock options, which could significantly dilute existing shareholders upon exercise.
- Revenue Model: Confirm that the company has no current revenue streams and relies entirely on equity financing, debt conversion, and grants.